The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent beta-thalassemia in August 2022, and exagamglogene autotemcel (exa-cel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback